These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 19581216)

  • 1. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk.
    Bozina N; Bradamante V; Lovrić M
    Arh Hig Rada Toksikol; 2009 Jun; 60(2):217-42. PubMed ID: 19581216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis.
    Elfaki I; Mir R; Almutairi FM; Duhier FMA
    Asian Pac J Cancer Prev; 2018 Aug; 19(8):2057-2070. PubMed ID: 30139042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450 pharmacogenetics and cancer.
    Rodriguez-Antona C; Ingelman-Sundberg M
    Oncogene; 2006 Mar; 25(11):1679-91. PubMed ID: 16550168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
    Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
    Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases.
    Daly AK
    Adv Pharmacol; 2015; 74():85-111. PubMed ID: 26233904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 gene polymorphism and cancer.
    Agundez JA
    Curr Drug Metab; 2004 Jun; 5(3):211-24. PubMed ID: 15180491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers.
    He X; Feng S
    Curr Drug Metab; 2015; 16(10):850-63. PubMed ID: 26652254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphism of cytochrome P450 as a biomarker of susceptibility to environmental toxicity.
    Hong JY; Yang CS
    Environ Health Perspect; 1997 Jun; 105 Suppl 4(Suppl 4):759-62. PubMed ID: 9255558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
    Nebert DW; McKinnon RA; Puga A
    DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphism and toxicology--with emphasis on cytochrome p450.
    Johansson I; Ingelman-Sundberg M
    Toxicol Sci; 2011 Mar; 120(1):1-13. PubMed ID: 21149643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes].
    Ozawa S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1998; (116):69-81. PubMed ID: 10097514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals.
    Wolf CR
    IARC Sci Publ; 1991; (115):281-7. PubMed ID: 1820342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 genetic polymorphisms of Mexican indigenous populations.
    Sosa-Macías M; Llerena A
    Drug Metabol Drug Interact; 2013; 28(4):193-208. PubMed ID: 24145057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variability in susceptibility and response to toxicants.
    Ingelman-Sundberg M
    Toxicol Lett; 2001 Mar; 120(1-3):259-68. PubMed ID: 11323184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450 Structure, Function and Clinical Significance: A Review.
    Manikandan P; Nagini S
    Curr Drug Targets; 2018; 19(1):38-54. PubMed ID: 28124606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro assessment of the allelic variants of cytochrome P450.
    Hiratsuka M
    Drug Metab Pharmacokinet; 2012; 27(1):68-84. PubMed ID: 22041138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism.
    Ikawa S; Uematsu F; Watanabe K; Kimpara T; Osada M; Hossain A; Sagami I; Kikuchi H; Watanabe M
    Pharmacogenetics; 1995; 5 Spec No():S154-60. PubMed ID: 7581487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
    Ingelman-Sundberg M; Sim SC; Gomez A; Rodriguez-Antona C
    Pharmacol Ther; 2007 Dec; 116(3):496-526. PubMed ID: 18001838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450 in Cancer Susceptibility and Treatment.
    Mittal B; Tulsyan S; Kumar S; Mittal RD; Agarwal G
    Adv Clin Chem; 2015; 71():77-139. PubMed ID: 26411412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.